Business Wire

VA-REGULA

3.7.2024 08:01:34 CEST | Business Wire | Press release

Share
Regula Responds to Forensic Experts' Needs with Fast and Intuitive Operating Software

Regula, a global developer of forensic devices and identity verification solutions, has released a significant update to its operating software, Regula Forensic Studio. This major revamp enhances the functionality of forensic devices, improves usability, streamlines operations, and allows for more precise document examination.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240702630951/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

A forensic expert examines a banknote with the help of a Regula device and Regula Forensic Studio software (Photo: Regula) 

Compatible with Regula’s most recent advanced forensic devices, including the company’s flagship dual-video spectral comparator, Regula 4308, Regula Forensic Studio software facilitates manual examination of handwritten texts, banknotes, travel and identity documents, collectibles, and more. Supplied in a bundle with forensic devices and available out-of-the-box, Regula Forensic Studio can operate all Regula devices in a forensic laboratory, creating a smooth user experience and allowing for a wide range of examinations.

The new features and improvements in Regula Forensic Studio significantly elevate the user experience, as well as the convenience, speed, and accuracy of forensic examination.

Crucial examination speed and precision enhancements include:

  • A new cross-platform architecture that significantly streamlines document processing and reporting, and ensures full compatibility with all popular operating systems, such as Windows, Linux, and macOS.
  • The possibility of creating predefined scenarios (macros) for repetitive tasks, which makes it possible to automate the verification process for certain types of documents. For example, if an expert needs to verify a wad of banknotes, they can automatically record the sequence of checks (including all the lighting and filtering techniques) for one banknote, and auto-repeat it for the rest of the wad. Not only does this feature streamline the whole process, but also eliminates human-related errors.
  • Fully automated ID verification in mere seconds through seamless integration with Regula Document Reader SDK, which instantly recognizes the document type and validates all its data from MRZs, RFID chips, barcodes, and performs available security checks.
  • Enhanced integration with the Information Reference System (IRS), which makes it simple to compare an examined document to its reference image from the database. Thanks to real-time sync between RFS and the Information Reference System, the device's active light source is switched to the one used in the reference sample, and vice versa. This leads to more quick and efficient examinations.
  • Automated banknote residual area measurement, a new feature that was added as a response to customers’ needs. It uses banknote references from the Regula IRS to automatically measure the undamaged area of a banknote and determine if it can be accepted by the bank.

Key usability enhancements include:

  • A new intuitive user-friendly interface.
  • Multi-screen support to allow users to drag and drop application tabs between monitors, which is especially convenient when working with several images.
  • Colored image superimposition, a new feature that highlights different elements of two images for easier comparison.
  • Pseudocolor visualization, a feature that uses substitute bright colors to highlight areas within the same color (like some indistinguishable shades of gray) for better visualization.
  • Automatic detection of Machine Identification Code (MIC), a new feature that detects a unique yellow-dot pattern color laser printers and copiers leave on paper sheets. This helps identify the source of printed documents.

“In the crowded field of ID verification, Regula has distinguished itself by constantly improving, as well as adopting a customer-centric approach at the core of our research and development. The updated Regula Forensic Studio software has become notably faster and more efficient. It reflects feedback from external forensic experts and our customers, and incorporates features designed to address specific use cases and improve operations. This user-centric approach helps us boost the functionality of our solutions and meet the evolving needs of our customers in the most efficient way,” says Ihar Kliashchou, Chief Technology Officer at Regula.

To see the full list of new features and capabilities and learn more about the recent update of Regula Forensic Studio, please visit Regula’s website.

About Regula

Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.

Learn more at www.regulaforensics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240702630951/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release

TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica

European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt

Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release

OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,

The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 10:00:00 CEST | Press release

Gabriele Salvatores, together with Rob Minkoff, Catherine Hardwicke, Jed Weintrob, Christina Lee Storm, Nils Hartmann, Guillem Martinez Roura, Filippo Rizzante, Giacomo Mineo, Brian Welk and Denise Negri, will judge the short films in competition based on creativity, production quality and the use of Artificial Intelligence. Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, wh

Bregal Milestone Announces Majority Growth Investment in CoreGo, a Leading European Open-Loop Payment and Event Technology Company29.4.2026 10:00:00 CEST | Press release

Investment follows over 98% annual growth and supports CoreGo’s continued market expansion Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in CoreGo Oy ("CoreGo" or the "Company"), a leading provider of open-loop payments and integrated technology solutions for festivals, sports events, and venues across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427991105/en/ Founded in Helsinki in 2015 by Hannu Elomaa and CTO Nikoteemu Väänänen, CoreGo has built one of Europe's most differentiated open-loop payment infrastructure and event technology businesses. Serving approximately 250 customers across the Nordics and DACH region, the Company delivers an integrated showtime-critical suite of solutions through CoreGo Cloud, unifying payments, access, networks, and data into a single real-time operating system. CoreGo’s in-house private network

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye